New combo aims to deepen remissions in blood cancer patients

NCT ID NCT07271667

First seen Jan 05, 2026 · Last updated May 05, 2026 · Updated 13 times

Summary

This phase 2 study tests whether adding the experimental drug emavusertib to an approved targeted therapy (zanubrutinib) can improve outcomes for adults with chronic lymphocytic leukemia (CLL) and related B-cell cancers. About 108 participants will receive the combination to see if it can make cancer undetectable or shrink tumors. The goal is better disease control, not a cure, as ongoing treatment is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mt Sinai Comprehensive Cancer Center

    RECRUITING

    Miami Beach, Florida, 33140, United States

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Texas Oncology - Sammons Cancer Center

    RECRUITING

    Dallas, Texas, 75246, United States

Conditions

Explore the condition pages connected to this study.